TXG vs. VNT, ST, CAMT, MIR, TRNS, SENS, CTKB, LAB, ALNT, and EYPT
Should you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Vontier (VNT), Sensata Technologies (ST), Camtek (CAMT), Mirion Technologies (MIR), Transcat (TRNS), Senseonics (SENS), Cytek Biosciences (CTKB), Standard BioTools (LAB), Allient (ALNT), and EyePoint Pharmaceuticals (EYPT). These companies are all part of the "measuring and control equipment" industry.
10x Genomics vs.
Vontier (NYSE:VNT) and 10x Genomics (NASDAQ:TXG) are both business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.
In the previous week, 10x Genomics had 16 more articles in the media than Vontier. MarketBeat recorded 36 mentions for 10x Genomics and 20 mentions for Vontier. Vontier's average media sentiment score of 0.74 beat 10x Genomics' score of -0.08 indicating that Vontier is being referred to more favorably in the media.
Vontier has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.
10x Genomics received 16 more outperform votes than Vontier when rated by MarketBeat users. However, 51.76% of users gave Vontier an outperform vote while only 51.72% of users gave 10x Genomics an outperform vote.
Vontier has a net margin of 14.17% compared to 10x Genomics' net margin of -29.90%. Vontier's return on equity of 43.22% beat 10x Genomics' return on equity.
Vontier has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Vontier, indicating that it is currently the more affordable of the two stocks.
95.8% of Vontier shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 0.8% of Vontier shares are held by company insiders. Comparatively, 10.0% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Vontier presently has a consensus target price of $45.43, indicating a potential upside of 17.91%. 10x Genomics has a consensus target price of $20.57, indicating a potential upside of 84.53%. Given 10x Genomics' higher possible upside, analysts clearly believe 10x Genomics is more favorable than Vontier.
Summary
Vontier beats 10x Genomics on 11 of the 18 factors compared between the two stocks.
Get 10x Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
10x Genomics Competitors List
Related Companies and Tools
This page (NASDAQ:TXG) was last updated on 2/21/2025 by MarketBeat.com Staff
